Atlas Insurance will now include COVID insurance under its travel insurance product offer, it has announced.

This aims to ensure that travellers insured with Atlas will be covered in relation to certain COVID related difficulties, the company explains.

Such coverage is available under the Atlas Travelpak policy at no additional cost to the regular premium and is intended to provide coverage in circumstances of cancellations, and other eventualities due to a number of circumstances resulting from COVID-19.

“With several countries achieving encouraging results in the fight against COVID-19, it was only normal that people are now starting to consider their travel plans again”, explained Matthew von Brockdorff, Managing Director and CEO of Atlas Insurance PCC Ltd.

“For this reason, Atlas Insurance has upgraded its Travelpak policy, by offering coverage for travellers who might be faced with COVID-related difficulties when abroad. The product will certainly provide the needed peace of mind to our customers, who are eager to travel once again”, he added.

Under the Atlas COVID cover, travellers will be able to claim any cancellation expenses if they contract COVID in the fourteen days before they are due to travel and will be covered if they are denied boarding being told they are showing symptoms of COVID.

The cover will also allow travellers to claim expenses for a missed departure due to an unusually long delay for results to be received, or cancellation due to a close relative, travelling companion or host abroad contracting COVID. They will also be covered if they are forced to quarantine or hospitalised due to the virus while abroad.

Atlas is joined by Gasan Mamo in having expanded its travel coverage to include COVID-related issues.

Atlas Insurance PCC Limited (C5601) is a cell company authorised under the Insurance Business Act 1998 to carry on general insurance business and is regulated by the Malta Financial Services Authority. The non-cellular assets of the company may be used to meet losses incurred by the cell in excess of their assets.